If you have been reading about thymosin beta-4 fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
intron Also intragenic region. Any nucleotide sequence within a functional gene that is removed by RNA splicing during post-transcriptional modification of the mRNA primary transcript and is therefore absent from the final mature mRNA. The term refers to both the sequence as it exists within a DNA molecule and to the corresponding sequence in RNA transcripts. Contrast exon.
== Protein structure and Terminology == Proteins are chains of amino acids joined together by peptide bonds. Many conformations of this chain are possible due to the rotation of the main chain about the two torsion angles φ and ψ at the Cα atom. This conformational flexibility is responsible for differences in the three-dimensional structure of proteins.
continuity (conservation of mass), conservation of linear momentum, conservation of angular momentum, conservation of energy. The study of fluids is fluid mechanics, which is subdivided into fluid dynamics and fluid statics depending on whether the fluid is in motion.
=== Structure === The nano-sized structure of nanocapsules allows permeating through basal membranes, which makes them effective carriers of medicine in biological systems. The specific processing of nanocapsules gives them unique properties in how they release drugs in certain situations. Generally, there are three physico-chemical release mechanisms that are used to release the drug or medicine from the polymeric shell of the nanocapsule.
Sources: en.wikipedia.org
=== Vegetable === Many plants have coagulating properties. Homer suggests in the Iliad that the Greeks used an extract of fig juice to coagulate milk. Other examples include several species of Galium, dried caper leaves, nettles, thistles, mallow, Withania coagulans (also known as Paneer Booti, Ashwagandh and the Indian Cheesemaker), and ground ivy. Some traditional cheese production in the Mediterranean uses enzymes from thistle or Cynara (artichokes and cardoons). Phytic acid, derived from unfermented soybeans, or fermentation-produced chymosin (FPC) may also be used. Vegetable rennet might be used in the production of kosher and halal cheeses, but nearly all kosher cheeses are produced with either microbial rennet or FPC. Commercial so-called vegetable rennets usually contain an extract from the mold Rhizomucor miehei described below.
On December 18, 2018, Kennedy voted against the First Step Act, a criminal justice reform bill that reduced the prison sentences of some federal inmates. He said, "I voted against this bill because the most important goal of the criminal justice system for American families is justice. This bill is backwards. It favors criminals over victims. It forgets that the ultimate goal is justice. We’ve seen what’s happened with so-called criminal justice reform in Louisiana. People are literally getting killed." On October 5, 2018, Kennedy introduced a Small Business Administration Disaster Loan bill to stop the agency from dropping SBA loan limits from $25,000 to $14,000 to ensure businesses have funds to rebuild following natural disasters. The bill passed the Senate with unanimous consent. President Trump signed it into law on November 29, 2018. On November 15, 2018, Kennedy introduced the National Flood Insurance Program Extension Act, a bill that amended the National Flood Insurance Act of 1968 to reauthorize the National Flood Insurance Program until June 1, 2019, to avoid a lapse in the program. The bill passed the Senate with unanimous consent and passed the House with a vote of 315–48. Trump signed the bill into law on December 21, 2018. In 2018, Kennedy worked with Senator Joe Manchin on the Justice Against Corruption on K Street (JACK) Act. The bill was named after Jack Abramoff, a lobbyist who was convicted of fraud, corruption, and conspiracy.
The Selous Scouts also sought to increase the divisions between the ZANLA and ZIPRA by posing as members of one group and then attacking members of the other group. These tactics became publicly known and embarrassed the government. The Selous Scouts were probably responsible for killing black business owners in rural areas who provided support for the insurgents. These killings were conducted secretly. Special Branch provided the Selous Scouts with poisoned clothing, food, beverages and medicines that the unit inserted into the guerrilla supply chains. The use of contaminated supplies resulted in the reported deaths of over 800 guerrillas, and the likely death toll probably reached well over 1,000. The Rhodesian Directorate of Military Intelligence estimated in 1978 that the Selous Scouts were responsible for 68% of insurgent fatalities within Rhodesia. These casualties largely resulted from attacks by Rhodesian Army units on insurgents located by the Selous Scouts. However, the unit's ruthless tactics were counter-productive as they contributed to further alienating Rhodesia's black population from the government. This formed part of broader flaws in the Rhodesian counter-insurgency strategy, and the historian Jakkie Cilliers has written that "the Selous Scouts were merely the instruments of an overly aggressive and punitive strategy, simply directed at killing as many insurgents as possible and punishing the rural black population to force them to desist from support for the insurgent forces. The apparent success of the Selous Scouts led to the unit being glamorised.
This phenomenon was used in the design of light meters and similar devices. Selenium's semiconductor properties found numerous other applications in electronics. The development of selenium rectifiers began during the early 1930s, and these replaced copper oxide rectifiers because they were more efficient. These lasted in commercial applications until the 1970s, following which they were replaced with less expensive and even more efficient silicon rectifiers. Selenium came to medical notice later because of its toxicity to industrial workers. Selenium was also recognized as an important veterinary toxin, which is seen in animals that have eaten high-selenium plants. In 1954, the first hints of specific biological functions of selenium were discovered in microorganisms by biochemist, Jane Pinsent. It was discovered to be essential for mammalian life in 1957. In the 1970s, it was shown to be present in two independent sets of enzymes. This was followed by the discovery of selenocysteine in proteins. During the 1980s, selenocysteine was shown to be encoded by the codon UGA. The recoding mechanism was worked out first in bacteria and then in mammals (see SECIS element).
==== Elimination ==== More than 55% of THC is excreted in the feces and approximately 20% in the urine. The main metabolite in urine is the ester of glucuronic acid and 11-OH-THC and free THC-COOH. In the feces, mainly 11-OH-THC was detected. Estimates of the elimination half-life of THC are variable. THC was reported to have a fast initial half-life of 6 minutes and a long terminal half-life of 22 hours in a population pharmacokinetic study. Conversely, the Food and Drug Administration label for dronabinol reports an initial half-life of 4 hours and a terminal half-life of 25 to 36 hours. Many studies report an elimination half-life of THC in the range of 20 to 30 hours. 11-Hydroxy-THC appears to have a similar terminal half-life to that of THC, for instance 12 to 36 hours relative to 25 to 36 hours in one study. The elimination half-life of THC is longer in heavy users. This may be due to slow redistribution from deep compartments such as fatty tissues, where THC accumulates with regular use.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.